AzTrials
AzTrials

Intertrochanteric FractureNCT02627040

Intertrochanteric Femoral Fracture Fixation Trial

A study testing InterTan Intertrochanteric Nail and Gamma 3 Intertrochanteric Nail in people with Intertrochanteric Fracture and Hip Fracture, run by Florida Orthopaedic Institute at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The main goal of the study is to determine which cephalomedullary nail results in a better functional outcome for the patient with an unstable intertrochanteric hip fracture. Subjects will be randomized to fixation with either a Gamma3 cephalomedullary nail or an InterTan cephalomedullary nail. Read more about this study

Who is it for?
Ages 60 years and older
Conditions the study is for
Intertrochanteric Fracture, Hip Fracture
What is being tested?
InterTan Intertrochanteric Nail and Gamma 3 Intertrochanteric Nail
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
95 participants
Where
2 sitesUnited States
Study dates
30 Nov 2015to Sep 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients surgically treated for an intertrochanteric femur fracture at Tampa General Hospital.
  • Skeletally mature patients over the age of 60; both genders.
  • Community ambulators.

Who cannot join

  • Patients with ipsilateral lower extremity injury
  • Patients under age 60
  • Co-existent, severe knee or back problems
  • Muscle contracture around the knee or hip joint
  • Individuals who have had TKA within 6 months
  • Body mass index (BMI; kg/m2) >40
Show all 11Show fewer
  • Suspicious of pathologic fracture (tumor in origin)
  • Pre-op mobility: Non ambulatory; ambulatory indoors with living support
  • Cognitive impairment or dementia
  • Prisoners or impending incarceration
  • Homeless or no stable address.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Brandon Regional Hospital

    Brandon, Florida, 33511

  • Tampa General Hospital

    Tampa, Florida, 33606

Other trials in United States

About this study

Official title: A Prospective Randomized Trial of Intertrochanteric Femoral Fractures Treated With a Single Screw Versus a Two-integrated Screw Cephalo-medullary Nail.

The main goal of the study is to determine which cephalomedullary nail results in a better functional outcome for the patient with an unstable intertrochanteric hip fracture. Subjects will be randomized to fixation with either a Gamma3 cephalomedullary nail or an InterTan cephalomedullary nail. Outcomes will be reviewed over a 12 month follow-up period.

Read the detailed description

Primary Hypotheses:

Patients who maintain their initial fracture reduction and subsequent position over time with minimal femoral neck shortening and varus will demonstrate significantly improved functional abilities, including gait and abductor function.

Secondary Objective:

  • Whether radiographic differences in femoral neck shortening and varus collapse translate into a worse functional outcome to the patient.
  • Whether there are differences in mortality between treatments
  • Whether there is a time frame follow up after which there is no difference in outcomes.
  • Evaluate the device used for fracture stabilization as a potentially contributing factor for maintenance of normal or near-normal abductor function and gait.

Primary Outcome:

The primary outcome will be functional abilities at 3, 6 and 12 months after injury. The following measures of functional ability will be utilized:

Methods:

This is a prospective, randomized non-blinded study. Patients will be identified as they present to the orthopaedic trauma service of Tampa General Hospital with a qualifying injury to determine their interest in participating in the study. Written informed consent will be obtained prior to initiation of any study procedures.

Group A will undergo cephalomedullary nail-based single screw intertrochanteric hip fracture fixation device (Gamma 3 nail). Group B will receive the integrated dual screw intertrochanteric hip fracture fixation device (Intertan nail). Patient outcomes will be analyzed using intention to treat principles. Following randomization assignment, surgeons will all follow the identical described surgical technique, with the only variable being the implant used. Post-operative immobilization and time to weight bearing and rehabilitation protocols will be again identical for all patients regardless of fixation technique.

Being tested
InterTan Intertrochanteric Nail, Gamma 3 Intertrochanteric Nail
Medical subject headings
Hip Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • InterTan Intertrochanteric NailDevice

    Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail

  • Gamma 3 Intertrochanteric NailDevice

    Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail

Study groups in NCT02627040
Study groupRoleWhat they receive
InterTan Intertrochanteric NailActive comparator'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
Receives: Device: InterTan Intertrochanteric Nail
Gamma 3 Intertrochanteric NailActive comparator'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
Receives: Device: Gamma 3 Intertrochanteric Nail

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hip Function

    Hip Function measured with Harris Hip Score.

    Measured: 6 months post-operatively

Secondary outcomes (4)
  1. Functional outcome

    Functional outcome will be measured using the following outcome measurement: Gait analysis using MiniSun's IDEEA® LifeGait System, a portable device for assessment of functional gait outcomes.

    Measured: 6 months post-operatively

  2. Walking ability

    Subjects will wear a pedometer applied in the immediate post-operative period, and will continue to wear it for 3 months. Total walking steps will be measured.

    Measured: 3 months post-operatively

  3. Hip range of motion

    Range of motion of hip measured with Harris Hip Score.

    Measured: 6 months post-operatively

  4. Hip Pain

    Pain measured with Harris Hip Score.

    Measured: 6 months post-operatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2015 (estimated)
  2. Study start30 Nov 2015
  3. Primary completion31 Aug 2020 (estimated)
  4. Study completionSep 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
95 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02627040
Sponsor's protocol ID
00023144
Status last verified
Nov 2019
First submitted
25 Nov 2015
Last updated
18 Nov 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No: There is no plan to share data.

Questions about this trial

What is this clinical trial studying?

A study testing InterTan Intertrochanteric Nail and Gamma 3 Intertrochanteric Nail in people with Intertrochanteric Fracture and Hip Fracture, run by Florida Orthopaedic Institute at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hip Function (time frame: 6 months post-operatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in